On Nov. 13, 2017, the Department of Transportation (DOT) published a final rule that, among other items, expands DOT’s current drug testing panel to include certain semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone). Testing for methylenedioxyethylamphetamine (MDEA) has been removed while methylenedioxyamphetamine (MDA) has been added as an initial test analyte.
The final rule also clarifies existing drug testing program provisions and definitions, makes technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. The final rule becomes effective Jan. 1, 2018.
“The opioid crisis is a threat to public safety when it involves safety-sensitive employees involved in the operation of any kind of vehicle or transport,” said DOT Secretary Elaine L. Chao. “The ability to test for a broader range of opioids will advance transportation safety significantly and provide another deterrence to opioid abuse, which will better protect the public and ultimately save lives.”
Click here to read more from DOT.
Click here to read the final rule as published in the Federal Register.
Related News
- Local #823 member killed in on-duty collision
- “Three Pack” attacks: SMART councils meet to fortify union in California
- The Safety Of Our BNSF Brothers And Sisters Is Not For Sale!
- Tragic Collision in Pecos, Texas Claims Two Lives
- SMART-TD union announces the passage of the Railroad Employee Equity and Fairness Act (REEF)
- SMART-TD member elected to lead Kansas worker group
- SMART-TD condemns Union Pacific’s lease to Central Oregon Pacific Railroad
- Sharp-eyed conductor saves two lives in winter crossing accident
- Union Takes Bold Step To Force Congress To Act On Rail Safety
- Fundraiser established for fallen brother, Local Chairperson of 1518, Steve Bryant